Carl's away, so I've punched out a bite-sized Evening Wrap ASX 200 ticked higher and finished the week up 1.19% Wesfarmers shares soared after a Goldman Sachs upgrade Let's dive in. Today in Review ...

Morgans analyst Scott Power says there's been a rotation back into small healthcare stocks as EBR Systems records a massive ... Read More The post Scott Power: Cardiac pacing device developer EBR hits ...

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

Kathleen P. Gallagher, Chief Program Officer at Avidity Biosciences, Inc. (NASDAQ:RNA), has sold shares of the company worth $206,799, according to a recent filing with the Securities and Exchange ...

As the percentage of the global population over 65 continues to increase, the popularity of anti-aging stocks is rising in tandem thanks to advancements in technology and a growing body of research on ...

Opus Genetics, Inc., a pharmaceutical company specializing in preparations with a market capitalization of $35.67 million, has announced the date for its 2025 Annual Meeting of Stockholders. According ...

Following a filing revealing its intent to go public in the US on 6 January, artificial pancreas maker Beta Bionics has now ...

Andrew Dudum, the Chief Executive Officer of Hims & Hers Health, Inc. (NYSE:HIMS), recently executed a series of stock transactions, according to a Form 4 filing with the Securities and Exchange ...

Sandip Kapadia, the Chief Financial Officer of Harmony Biosciences Holdings , Inc. (NASDAQ:HRMY), a pharmaceutical company ...

The stock of Vertex Pharmaceuticals Incorporated VRTX has declined almost 13% in the past six months. A key reason for the stock price decline was unimpressive data from a phase II study on its key ...

Helius Medical Technologies, Inc. (Nasdaq: HSDT) announced it has exceeded its initial enrollment target for the stroke registrational program evaluating its Portable Neuromodulation Stimulator (PoNS® ...

Study participants in the PK run-in study are randomized 2:1 to receive either nomlabofusp or placebo daily for seven days. Following assessment of safety and PK data of each successive cohort, ...